NYU Study Validates Groundbreaking Heart Disease Risk Prediction Tool

A new tool for predicting heart disease risk has been validated by researchers at NYU Langone Health. The study confirms the effectiveness of the American Heart Association’s PREVENT tool in assessing cardiovascular risks worldwide. Published in Nature Medicine, the findings suggest a major step forward in clinical prevention strategies. The PREVENT tool was tested on data from over 6.4 million people across North America, Europe, and Asia. Its ability to predict 10- and 30-year risks of heart attack, stroke, and heart failure proved superior to older models like the Pooled Cohort Equation (PCE). The improvement was particularly clear in low-to-moderate risk groups.

Adding kidney function data, such as albuminuria levels, further boosted the tool’s accuracy. Researchers found this enhancement critical for refining risk assessments. The study was backed by the National Institute of Diabetes and Digestive and Kidney Diseases and the US National Kidney Foundation. Beyond prediction, PREVENT helps tailor treatment plans. Clinicians can now better determine the need for cholesterol-lowering drugs, blood pressure medications, and lifestyle advice. The tool’s global validation also opens the door for unified prevention guidelines across countries.

The validation of PREVENT provides clinicians with a more precise method for assessing heart disease risk. Its widespread adoption could standardise prevention efforts and improve patient outcomes. The study’s publication in Nature Medicine underscores its importance in modern cardiovascular care.